PCSK9 inhibitors (Biosortia Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePCSK9 inhibitors (Biosortia Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaCoronary Artery Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiosortia Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiosortia Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHypercholesterolemiaCoronary Artery Disease

Other Information

ATC CodeN/A
Related LinksN/A